Research / ANGI / Fundamental state Inspectable configuration
State dimensions Filing 0001705110-21-000094 General Corporate
Debt relative to revenue 86th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.debt_to_revenue
117.39% · OPTIONAL · VALID
Capex intensity 50th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.capex_revenue_ratio
4.03% · OPTIONAL · VALID
Operating cash generation 23th Own-history percentile · N=13
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
10.43% · OPTIONAL · VALID
Revenue growth 30th Own-history percentile · N=10
Evidence method Yoy · gp.fundamentals.revenue
12.25% · CORE · VALID
Operating margin 7th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.operating_margin
-7.77% · CORE · VALID
R&D intensity 14th Own-history percentile · N=14
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
4.45% · OPTIONAL · VALID
SBC intensity 7th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
2.27% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 31 states Self-history eligible
Sep 30, 2021 7/7 normalized Level 3 Dec 31, 2021 6/6 normalized Level 3 Mar 31, 2022 6/6 normalized Level 3 Jun 30, 2022 6/7 normalized Level 3 Sep 30, 2022 6/7 normalized Level 3 Dec 31, 2022 6/7 normalized Level 3 Mar 31, 2023 6/7 normalized Level 3 Jun 30, 2023 6/7 normalized Level 3 Sep 30, 2023 6/7 normalized Level 3 Dec 31, 2023 5/6 normalized Level 3 Mar 31, 2024 5/6 normalized Level 3 Jun 30, 2024 6/6 normalized Level 3 Sep 30, 2024 6/6 normalized Level 3 Dec 31, 2024 6/6 normalized Level 3 Mar 31, 2025 7/7 normalized Level 3 Jun 30, 2025 7/7 normalized Level 3 Sep 30, 2025 7/7 normalized Level 3 Dec 31, 2025 6/6 normalized Level 3 Mar 31, 2026 7/7 normalized Level 3 Jun 30, 2026 7/7 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 182.41%
Current 117.39%
Delta -65.02% Capex Intensity Decreased
Previous 4.84%
Current 4.03%
Delta -0.81% Cash Generation Increased
Previous 3.96%
Current 10.43%
Delta 6.46% Growth Decreased
Previous 12.62%
Current 12.25%
Delta -0.38% Profitability Decreased
Previous 0.03%
Current -7.77%
Delta -7.80% R And D Intensity Decreased
Previous 4.66%
Current 4.45%
Delta -0.21% Sbc Intensity Increased
Previous 0.53%
Current 2.27%
Delta 1.74% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.